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CASE STUDY
Methotrexate-induced cutaneous ulceration 
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Abstract: Methotrexate-induced cutaneous ulceration has rarely been reported in patients with 
mycosis fungoides. We report 4 patients with mycosis fungoides who developed cutaneous 
ulceration as an initial manifestation of methotrexate toxicity. Methotrexate dose at the time of 
ulceration ranged from 10–60 mg. All 4 patients were erythrodermic, which may have predisposed 
them to this toxic effect. It is important to recognize cutaneous ulceration as an uncommon, 
but potentially serious, side effect of methotrexate in these patients, and to differentiate it from 
ulceration due to progressive lymphoma.
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Introduction
The use of methotrexate as a therapeutic agent in the treatment of cutaneous T-cell 
lymphoma (CTCL) is well established (McDonald and Bertino 1978; Zackheim and 
Epstein 1989; Zackheim et al 1996, 2003). There have been rare reports of cutaneous 
erosion and/or ulceration occurring in patients with mycosis fungoides treated with 
methotrexate (McDonald and Bertino 1978; Zackheim and Epstein 1989; Zackheim 
et al 1996). However, methotrexate-induced cutaneous ulceration may be misdiag-
nosed when treating patients with mycosis fungoides, as it can be easily mistaken for 
ulceration associated with disease progression.
We report 4 patients with erythrodermic mycosis fungoides who developed cutane-
ous ulceration as a manifestation of methotrexate toxicity. In all patients the etiologic 
differential diagnosis included tumor ulceration due to progressive lymphoma.
Case reports
Patient 1
An 81-year-old previously healthy African-American male with a long history of 
patch stage mycosis fungoides, presented with multiple large cutaneous tumors 
involving most prominently the axillae and anterior thighs. Also present were numer-
ous hyperpigmented patches and plaques, covering approximately 35% of the skin 
surface. The tumors resolved with local radiotherapy, but his skin disease progressed 
to erythroderma.
The patient was placed on methotrexate 10 mg per week by mouth. Other medica-
tions were lorazepam and hydroxyzine. After 7 weeks of methotrexate therapy, the 
patient developed multiple angulated, clean-based erythematous ulcers involving the 
axillae, groin, buttocks, right thigh, and right posterior leg (Figure 1). Creatinine was 
1.4 mg/dL, blood urea nitrogen 18 mg/dL, hemoglobin 11.6 g/dL, white blood cell 
count 9,400 mm3, and platelet count 160,000 mm3. Biopsies of the ulcers revealed 
full-thickness epidermal loss with underlying necrosis of the papillary dermis, felt to Therapeutics and Clinical Risk Management 2008:4(5) 1136
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be highly consistent with methotrexate-induced cutaneous 
toxicity. Additionally, there was a moderately dense perivas-
cular and diffuse mixed inﬁ  ltrate of mononuclear cells and 
eosinophils in the superﬁ  cial and deep dermis, with many 
of the mononuclear cells having hyperchromatic nuclei. 
Similar cells with hyperchromatic nuclei were seen within the 
epidermis both singly and in groups. A viral culture obtained 
from a cutaneous ulcer was negative.
The methotrexate was discontinued and the ulcerations 
healed without further sequelae. The patient was subsequently 
treated with total skin irradiation with marked improvement 
of his erythroderma.
Figure 1 Multiple punched-out ulcers on the leg of an 81 year old African-American male on methotrexate for 7 weeks.
Figure 2 Biopsy of skin adjacent to ulcer revealing disorganization of epidermal cells, moderate pleomorphism and dyskeratosis; magniﬁ  cation × 400.Therapeutics and Clinical Risk Management 2008:4(5) 1137
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Patient 2
A 78-year-old Caucasian male with a two year history of 
patch stage mycosis fungoides, was seen with new devel-
opment of multiple cutaneous nodules, erythroderma, and 
severe pruritus.
The patient was begun on 40 mg per week of methotrexate 
intravenously. Other medications were potassium chloride, 
ﬂ  utamide and furosemide. Three weeks later he developed 
multiple 1- to 6-cm sharply marginated, oval, bleeding, 
shallow ulcers over the buttocks, posterior thighs, arms, 
upper back, and scalp. Blood urea nitrogen was 102 mg/dL, 
creatinine 2.4 mg/dL, hemoglobin 8.6 mg/dL, hematocrit 
25.5%, WBC 3,000/mm3, and platelet count 92,000/mm3. 
Viral culture from an ulcer was negative.
Skin biopsy from skin adjacent to an ulcer revealed disor-
ganization of epidermal cells, moderate pleomorphism, and 
dyskeratosis. A mild polymorphous inﬁ  ltrate of mononuclear 
cells with a few multinucleated giant cells was present in the 
upper dermis (Figure 2). These ﬁ  ndings were considered to 
be consistent with cutaneous methotrexate toxicity.
Methotrexate was discontinued and the patient was treated 
with oral VP16. The cutaneous ulcers re-epithelialized, but 
the patient expired two months later secondary to progressive 
mycosis fungoides.
Patient 3
A 77-year-old African-American female, with a 3-year history 
of patch stage mycosis fungoides, was seen because of disease 
progression to erythroderma. Examination revealed diffuse 
exfoliative erythroderma. Laboratory test results included: 
blood urea nitrogen 24 mg/dL, serum creatinine 1.3 mg/dL, 
hemoglobin 11.5 g/dL, hematocrit 34.4%, white blood cell 
count 6,100/mm3, and platelet count 276,000/mm3.
Methotrexate was started at a dose of 10 mg per week by 
mouth, and gradually escalated over 8 weeks to a dose of 40 
mg per week by mouth. Other medications were etretinate, 
mechlorethamine hydrochloride, and hydroxyzine. Twelve 
weeks after initiation of methotrexate, the patient developed 
multiple cutaneous erosions and ulcerations over her scalp, 
face, and trunk, with a 20 cm ulceration over her buttocks 
(Figure 3). Laboratory studies included: blood urea nitrogen 
13 mg/dL, serum creatinine 0.9 mg/dL, hemoglobin 10.4 g/dL, 
hematocrit 30.1%, white blood cell count 3,400/mm3, and 
platelet count 325,000/mm3. A skin biopsy obtained from tissue 
adjacent to an erosion revealed a few lymphocytes migrating 
into the epidermis. There was papillary dermal edema with a 
surrounding mild lymphocytic inﬁ  ltrate, melanophages and 
occasional eosinophils. Methotrexate was stopped, and no new 
ulcerations developed. Within three weeks, all of the ulcerations 
Figure 3 Large cutaneous ulcer over the buttocks in a 77 year old African-American female on methotrexate for 12 weeks.Therapeutics and Clinical Risk Management 2008:4(5) 1138
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had re-epithelialized. The patient was subsequently placed on 
a combination of deoxycoformycin intravenously and alpha-
interferon subcutaneously with an excellent clinical response.
Patient 4
A 67-year-old African-American male with a 4-year history 
of patch/plaque stage mycosis fungoides was seen because 
of progression to erythroderma. Cutaneous examination 
revealed a diffuse exfoliative erythroderma. Methotrexate 
was initiated at a dose of 50 mg per week intravenously, and 
six months later, this dose was increased to 60 mg per week 
intravenously. There were no concurrent medications. His 
erythroderma improved dramatically, and he was maintained 
on 60 mg methotrexate per week. Four and a half years later, 
he presented with multiple cutaneous erosions in the axil-
lae, groin, and gluteal cleft (Figure 4). Serum methotrexate 
level was 3 times the upper therapeutic limit. His laboratory 
studies included: blood urea nitrogen 92 mg/dL, serum 
creatinine 11.5 mg/dL, hemoglobin 13.9 g/dL, hematocrit 
42%, white blood cell count 1,100/mm3, and platelet count 
182,000/mm3.
It was determined that the patient had post-obstructive 
acute renal failure, with methotrexate toxicity secondary 
to decreased excretion of the drug. His methotrexate was 
discontinued, and he was treated with folate, leucovorin, 
intravenous ﬂ  uids and placement of a urinary catheter.
Histologic examination of a biopsy specimen, from skin 
adjacent to an erosion, showed vacuolar degeneration of the 
basal cells and a sparse lymphocytic inﬁ  ltrate containing 
several melanophages (Figure 5). Histologic examination 
of a biopsy specimen from the margin of an erosion showed 
almost complete epidermal necrosis and a mild lymphocytic 
inﬁ  ltrate with melanophages (Figure 6).
As serum methotrexate levels normalized, the ulcers 
began to re-epithelialize, and no new ulcerations developed. 
His blood urea nitrogen and serum creatinine levels normal-
ized to 21 mg/dL and 1.3 mg/dL respectively. One month 
later, the ulcers were noted to be completely healed. The 
patient was subsequently restarted on methotrexate 30 mg 
per week intravenously, following a transurethral resection 
of the prostate, and no further ulcers developed.
Discussion
The occurrence of cutaneous ulceration as a side effect of 
methotrexate therapy in the treatment of psoriasis, has been 
occasionally reported (Baker 1970; Lawrence and Dahl 1982, 
Figure 4 Angulated ulcers occurring in a 72 year old African-American male after 5 years of methotrexate therapy.Therapeutics and Clinical Risk Management 2008:4(5) 1139
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1984; Reed and Sober 1983; Kaplan and Olsen 1988; Pearce 
and Braunstein 1996; Primka and Camisa 1997; Kazlow et al 
2003). In addition to the rare occurrence of a toxic epidermal 
necrolysis-like condition, two different patterns of ulcerations 
have been described in these patients; one type in psoriatic 
plaques and the other type in skin uninvolved by psoriasis 
but affected by other cutaneous pathology, such as stasis 
dermatitis or scars (Lawrence and Dahl 1984; Primka and 
Camisa 1997). In patients with cutaneous T-cell lymphoma, 
cutaneous ulcerations have only rarely been reported as a side 
effect of methotrexate therapy (McDonald and Bertino 1978; 
Zackheim and Epstein 1989; Zackheim et al 1996).
Cutaneous ulcerations have been described as a possible 
ﬁ  rst sign of methotrexate toxicity in psoriasis patients (Baker 
1970; Lawrence and Dahl 1982, 1984; Kaplan and Olsen 
1988; Pearce and Braunstein 1996). Likewise, the cases we 
present demonstrate that cutaneous ulceration may be the ﬁ  rst 
sign of methotrexate toxicity in patients with erythrodermic 
mycosis fungoides. In 3 of our patients, cutaneous ulceration 
developed after relatively short methotrexate treatment peri-
ods (3 weeks, 7 weeks, and 12 weeks). In the fourth patient, 
ulceration occurred after 5 years of methotrexate therapy, but 
in this patient methotrexate toxicity was clearly related to 
post-obstructive acute renal failure. There was a wide range 
of methotrexate dosages used at the time of ulceration, with 
10 mg being the lowest dose and 60 mg being the highest 
dose administered.
The most common risk factors in psoriatics who devel-
oped methotrexate-induced cutaneous ulceration, were 
alteration in methotrexate dosage, and concomitant use of 
nonsteroidal anti-inﬂ  ammatory drugs (Pearce and Braunstein 
1996). A number of drugs may inﬂ  uence the metabolism of 
methotrexate, or potentiate methotrexate-induced toxicity. 
These include salicylic acid and non-steroidal anti-inﬂ  amma-
tory drugs (Naldi and Grifﬁ  ths 2005). None of our patients 
were taking any of these medications, however. Patient 2 
was taking furosemide concomitantly with the methotrex-
ate, and it has been suggested that furosemide may produce 
toxic methotrexate levels by increasing methotrexate tubular 
secretion. However, experimental data in support of such an 
interaction is lacking (Lawrence and Dahl 1984). Impaired 
renal function may impair methotrexate elimination, caus-
ing methotrexate toxicity from increased serum levels of the 
drug (Pearce and Braunstein 1996). This likely contributed to 
toxicity in Patient 4 and possibly Patient 2. Because impaired 
renal function can predispose patients to toxic effects of 
Figure 5 Biopsy obtained adjacent to an erosion showing marked epidermal atrophy, vacuolar degeneration of the basal cells, and a sparse lymphocytic inﬁ  ltrate; 
magniﬁ  cation × 100.Therapeutics and Clinical Risk Management 2008:4(5) 1140
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methotrexate, including cutaneous ulceration, it is important 
to monitor renal status throughout treatment.
Methotrexate-induced cutaneous ulceration is rare in 
patients with no underlying skin disease (Aractingi et al 1992; 
Ben-Amitai et al 1998). One reported patient developed 
extensive cutaneous erosion after being given methotrexate 
intravenously to treat high-grade lymphoma (Aractingi et al 
1992) and another patient developed recurrent skin ulcers 
concurrent with methotrexate administration for seronegative 
arthralgias (Ben-Amitai et al 1998). Of particular note, all 
four of our patients were erythrodermic when they devel-
oped methotrexate-induced cutaneous ulceration, and the 
ulceration occurred primarily on erythrodermic skin, rather 
than at the sites of nodules/tumors. It appears that most of 
the CTCL patients previously reported to have developed 
methotrexate toxicity were also erythrodermic (Zackheim 
and Epstein 1989; Zackheim et al 1996). Many patients with 
erythroderma also have exfoliation. The epidermis of patients 
with exfoliative erythroderma has a shorter cellular turnover 
time and a higher rate of metabolic activity, and because 
methotrexate is an S-phase speciﬁ  c therapy, it is most active 
against rapidly dividing cells (Olsen 1991). This suggests that 
patients with erythrodermic mycosis fungoides may form a 
subset of mycosis fungoides patients more susceptible to 
methotrexate-induced cutaneous ulceration.
The mechanism of cutaneous necrosis and ulceration due 
to methotrexate therapy may be due to the antiproliferative 
effects of the drug. Methotrexate-induced skin necrolysis has 
been reported to be dose dependent, suggesting a toxic drug 
effect with the toxic dosage being dependent on the individual 
(Yang et al 2000). In patients with toxic serum levels, or pos-
sibly with an increased sensitivity to methotrexate, there may 
be signiﬁ  cant necrosis of dividing cells in a particular area of 
skin, to the point that there are no dividing cells in the basal 
layer to replace the layers undergoing sloughing. Because 
of the rapid turnover of epithelium in areas of erythroderma, 
erythrodermic patients may be particularly sensitive to this 
toxic effect.
The clinical and histological ﬁ  ndings in our four patients 
demonstrate that methotrexate therapy can induce cutaneous 
ulceration in patients with erythrodermic mycosis fungoides. 
It is important for clinicians to recognize this as an uncom-
mon but potentially serious side effect in patients with 
cutaneous T-cell lymphoma. The development of multiple 
cutaneous erosions or ulcerations, in a patient with advanced 
cutaneous mycosis fungoides, could easily be misconstrued 
Figure 6 Biopsy of skin from the margin of an erosion showing almost complete epidermal necrosis and mild lymphocytic inﬁ  ltrate with melanophages; magniﬁ  cation × 100.Therapeutics and Clinical Risk Management 2008:4(5) 1141
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to represent progressive lymphoma. If the methotrexate is 
continued, or the dosage is increased in this situation, it could 
lead to the development of more extensive ulceration, with 
the potential for sepsis and even death. Thus, patients with 
mycosis fungoides being treated with methotrexate, should 
be advised that should ulcers develop, the drug should be 
stopped and their physicians notiﬁ  ed immediately. Appropri-
ate treatment is dependent upon the correct diagnosis, and 
therefore, recognizing methotrexate as a possible cause of 
cutaneous ulceration in these patients is essential for appro-
priate patient management.
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